Soligenix, Inc.

SNGX

US8342236044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/06/2024 BST			5-day change	1st Jan Change
4.15 ^USD	-16.33%		-25.89%	-65.75%

05-23	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
05-23	Sector Update: Health Care Stocks Lower Thursday Afternoon	MT

Soligenix, Inc. Announces Resignation of Kevin J. Horgan as Chief Medical Officer and Senior Vice President

October 18, 2013 at 10:02 pm

Soligenix, Inc. announced that Kevin J. Horgan has notified that he will be resigning as Chief Medical Officer and Senior Vice President of the company effective October 18, 2013.

Latest news about Soligenix, Inc.

Sector Update: Health Care Stocks Retreat Late Afternoon	05-23	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	05-23	MT
Soligenix Seeks Shareholders' Approval for Reverse Stock Split; Shares Fall	05-23	MT
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma	05-16	CI
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	04-25	CI
Sector Update: Health Care Stocks Softer Late Afternoon	04-15	MT
Sector Update: Health Care Stocks Gain Monday Afternoon	04-15	MT
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	04-15	MT
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA	04-15	DJ
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	04-03	CI
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	02-08	CI
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	01-08	CI
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis	01-04	CI
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses	01-02	CI
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	12-01	MT
Sector Update: Health Care Stocks Higher Late Afternoon	11-30	MT
Top MIdday Gainers	11-30	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	11-30	MT
Sector Update: Health Care	11-30	MT
Soligenix Says US FDA Cleared Application for Trial of Behcet's Disease Aphthous Ulcers Treatment	11-30	MT
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease	11-30	CI
Soligenix Seeks Acquisitions	11-14	CI
Soligenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Soligenix, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.15 USD

Average target price

40 USD

Spread / Average Target

+863.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOLIGENIX, INC.	-65.75%	4.9M
VERTEX PHARMACEUTICALS INCORPORATED	+19.33%	125B
REGENERON PHARMACEUTICALS, INC.	+13.95%	109B
BIONTECH SE	-3.53%	24.74B
ARGENX SE	+2.71%	22.67B
GENMAB A/S	-9.95%	18.14B
WUXI APPTEC CO., LTD.	-41.48%	16.67B
BEIGENE, LTD.	-12.62%	16.64B
NEUROCRINE BIOSCIENCES, INC.	+0.99%	13.45B
SAREPTA THERAPEUTICS, INC.	+21.79%	11.32B

Bio Therapeutic Drugs

Soligenix, Inc.

Equities

SNGX

US8342236044

Biotechnology & Medical Research

Soligenix, Inc. Announces Resignation of Kevin J. Horgan as Chief Medical Officer and Senior Vice President

Latest news about Soligenix, Inc.

Chart Soligenix, Inc.

Company Profile

Income Statement Evolution

Ratings for Soligenix, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs